Published in J Clin Oncol on September 30, 2016
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study | NCT04115410
[The pathology of adverse events with immune checkpoint inhibitors]. Pathologe (2017) 0.78
The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. Eur J Nucl Med Mol Imaging (2017) 0.77
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. J Hematol Oncol (2017) 0.77
Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. Transl Lung Cancer Res (2017) 0.76
Do hospitals need oncological critical care units? J Thorac Dis (2017) 0.75
Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. J Immunother Cancer (2017) 0.75
Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab. ESMO Open (2017) 0.75
Special topics in immunotherapy and radiation therapy: reirradiation and palliation. Transl Lung Cancer Res (2017) 0.75
Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. Ther Clin Risk Manag (2017) 0.75
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J (2017) 0.75
Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. Radiographics (2017) 0.75
Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP). Intern Med (2017) 0.75
Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. Curr Oncol Rep (2017) 0.75
Risk of pneumonitis with different immune checkpoint inhibitors in NSCLC. Ann Transl Med (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 6.07
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2015) 5.42
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol (2006) 2.60
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol (2016) 2.06
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol (2015) 1.90
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med (2010) 1.66
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med (2015) 1.64
Toxicities of Immunotherapy for the Practitioner. J Clin Oncol (2015) 1.50
Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book (2015) 1.34
Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer (2006) 1.12
Pulmonary toxicity associated with erlotinib. Chest (2007) 1.02
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. Cancer Immunol Res (2016) 0.97
Bleomycin pulmonary toxicity: current status and future directions. Semin Oncol (1992) 0.83
Radiation pneumonitis and esophagitis in thoracic irradiation. Cancer Treat Res (2006) 0.82
Interstitial pneumonitis after total body irradiation: effect of partial lung shielding. Br J Haematol (1990) 0.80
Idiopathic interstitial pneumonias: a radiology-pathology correlation based on the revised 2013 American Thoracic Society-European Respiratory Society classification system. Curr Probl Diagn Radiol (2014) 0.80
Rare idiopathic intestinal pneumonias (IIPs) and histologic patterns in new ATS/ERS multidisciplinary classification of the IIPs. Eur J Radiol (2014) 0.79
Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): a pictorial review. Insights Imaging (2014) 0.79
Interstitial lung diseases in the hospitalized patient. BMC Med (2015) 0.78
A commentary on interstitial pneumonitis induced by docetaxel: clinical cases and systematic review of the literature. Tumori (2015) 0.75
Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol (1990) 0.75
Interstitial pneumonitis from treatment with gemcitabine. Hosp Pharm (2014) 0.75